Valuation: Insulet Corporation

Market Cap 11.59B 10.16B 9.39B 8.63B 16.32B 1,118B 16.57B 112B 43.99B 547B 43.53B 42.58B 1,884B P/E 2026 *
27.1x
P/E 2027 * 21x
Enterprise Value 11.67B 10.22B 9.45B 8.69B 16.42B 1,125B 16.68B 113B 44.27B 551B 43.81B 42.85B 1,896B EV / Sales 2026 *
3.51x
EV / Sales 2027 * 2.88x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insulet Corporation

1 day+2.02%
1 week+3.78%
Current month+9.93%
1 month+14.83%
3 months-17.85%
6 months-41.82%
Current year-41.12%
1 week 153.84
Extreme 153.84
169.85
1 month 138.79
Extreme 138.79
169.85
Current year 138.79
Extreme 138.79
299.8
1 year 138.79
Extreme 138.79
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Chairman 61 01/01/2019
Director/Board Member 61 27/07/2015
Director/Board Member 59 10/08/2017
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Other

Director

0 0%
01/07/26 Free

Director

1,355 0.0019%
30/06/26 Free

Director

144 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+2.02%+3.78%-41.11%-41.85% 11.36B
+0.97%+8.23%-17.80%-5.24% 175B
+0.11%-0.69%-7.05%-3.29% 106B
-1.27%+0.18%+3.80%+58.38% 59.91B
+0.66%+0.96%+37.64%+54.22% 51.95B
-2.33%+1.67%-13.63%-39.40% 43.58B
-2.29%-5.26% - - 33.65B
-1.25%+0.97%-9.77%-43.36% 29.58B
-1.65%-0.39%+67.06%-8.64% 25.31B
-1.55%-0.71%-4.93%-5.70% 21.23B
Average -0.66%+1.60%+1.58%-3.87% 55.84B
Weighted average by Cap. -0.23%+2.73%-2.76%+2.35%

Financials

2026 *2027 *
Net sales 3.32B 2.91B 2.69B 2.47B 4.67B 320B 4.74B 32.15B 12.6B 157B 12.47B 12.19B 539B 3.93B 3.44B 3.18B 2.92B 5.53B 379B 5.61B 38.03B 14.9B 185B 14.74B 14.42B 638B
Net income 432M 379M 350M 322M 608M 41.67B 617M 4.18B 1.64B 20.39B 1.62B 1.59B 70.21B 564M 494M 457M 420M 794M 54.41B 806M 5.46B 2.14B 26.62B 2.12B 2.07B 91.67B
Net Debt 75.17M 65.87M 60.9M 55.98M 106M 7.25B 107M 728M 285M 3.55B 282M 276M 12.21B -283M -248M -229M -211M -398M -27.28B -404M -2.74B -1.07B -13.35B -1.06B -1.04B -45.97B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
20/07/26 $167.37 +2.02% 1,652,176
17/07/26 $164.06 -0.23% 1,396,164
16/07/26 $164.43 +3.23% 1,498,524
15/07/26 $159.28 +0.10% 1,332,050
14/07/26 $159.12 -1.81% 1,942,227
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
167.37USD
Average target price
238.22USD
Spread / Average Target
+42.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock